TELA Bio, Inc. Income Statement
TELA|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
TELA Bio, Inc. reported $58M in revenue and $47M in net loss for FY2025. Revenue has grown at a 54.8% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $58.5M | $41.4M | $29.5M | $18.2M | $15.4M | $8.3M | $4.2M |
| Gross Profit | $40.1M | $27.0M | $18.8M | $11.2M | $9.3M | $2.9M | $2.5M |
| SG&A Expense | $14.9M | $13.9M | $12.5M | $10.1M | $6.2M | $4.9M | $5.0M |
| R&D Expense | $9.6M | $8.9M | $6.7M | $4.3M | $4.2M | $4.3M | $5.8M |
| Operating Income | -$44.1M | -$39.0M | -$29.5M | -$25.3M | -$19.2M | -$17.8M | -$16.9M |
| Interest Expense | - | - | $3.6M | $3.6M | $3.6M | $1.8M | $4.6M |
| Income Tax | -$144.0K | -$144.0K | - | - | - | - | - |
| Net Income | -$46.7M | -$44.3M | -$33.3M | -$28.8M | -$22.4M | -$21.1M | -$21.3M |
| EPS (Basic) | -$2.04 | -$2.72 | -$2.30 | -$2.23 | -$17.10 | - | - |
| EPS (Diluted) | -$2.04 | -$2.72 | -$2.30 | -$2.23 | -$17.10 | -$101.41 | - |
| Shares Outstanding | 39.4M | 24.5M | 19.2M | 14.5M | 14.4M | 11.4M | 295.7K |
| Gross Margin | 68.6% | 65.3% | 63.8% | 61.7% | 60.0% | 35.6% | 59.7% |
| Operating Margin | -75.4% | -94.2% | -100.0% | -138.8% | -124.1% | -214.9% | -398.7% |
| Profit Margin | -79.8% | -106.9% | -112.9% | -158.1% | -145.2% | -254.9% | -502.6% |